Two decades of commitment to malaria vaccine development: GlaxoSmithKline biologicals
Two decades of commitment to malaria vaccine development: GlaxoSmithKline biologicals
复制标题
DOI：
10.4269/ajtmh.2007.77.289
复制
发表时间：
2007-12-01
影响因子：
3.3
通讯作者：
Cahill, Conor P.
中科院分区：
文献类型：
--
作者：
Ballou, W. Ripley;Cahill, Conor P.
葛兰素史克生物制品公司（GSK）致力于开发安全有效的疟疾疫苗。其在该领域的研究计划始于1984年，并一直活跃到今天，使其在疫苗行业中无与伦比。尽管它与公共部门的几个主要组织合作，但这一努力要求GSK投入大量资金和人力资源，其合作伙伴严重依赖该公司的全球基础设施和在研究、先进临床开发、监管、大规模生产和商业化方面的专业知识。通过其开创性的商业模式以及与全球疫苗资助机构的合作，GSK致力于确保一旦获得批准，安全有效的疟疾疫苗将提供给每一个需要它的人。
GlaxoSmithKline Biologicals (GSK) is committed to the development of a safe and effective malaria vaccine. Its research program in this field was initiated in 1984 and has been continuously active to this day, making it unparalleled within the vaccine industry. Although it works in partnerships with several leading organizations from the public sector, this effort has required GSK to invest major financial and human resource commitments, and its partners rely heavily con the company's global infrastructure and expertise in research, advanced clinical development, regulatory, large-scale manufacturing, and cornmercialization. Through GSK's pioneering business model and working in partnership with global vaccine funding agencies, the company is committed to seeing that, once approved, a safe and effective malaria vaccine will be available to everyone that needs it.